![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF101 |
Gene summary for ZNF101 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF101 | Gene ID | 94039 |
Gene name | zinc finger protein 101 | |
Gene Alias | HZF12 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8IZC7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
94039 | ZNF101 | HCC1_Meng | Human | Liver | HCC | 1.41e-05 | -1.56e-02 | 0.0246 |
94039 | ZNF101 | HCC1 | Human | Liver | HCC | 7.91e-15 | 1.98e+00 | 0.5336 |
94039 | ZNF101 | HCC2 | Human | Liver | HCC | 1.85e-22 | 2.61e+00 | 0.5341 |
94039 | ZNF101 | HCC5 | Human | Liver | HCC | 1.65e-19 | 2.04e+00 | 0.4932 |
94039 | ZNF101 | S015 | Human | Liver | HCC | 2.10e-04 | 2.28e-01 | 0.2375 |
94039 | ZNF101 | S016 | Human | Liver | HCC | 2.77e-03 | 1.10e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF101 | SNV | Missense_Mutation | c.517N>T | p.Val173Leu | p.V173L | Q8IZC7 | protein_coding | tolerated(0.23) | benign(0.005) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF101 | SNV | Missense_Mutation | rs776249275 | c.1241N>T | p.Arg414Ile | p.R414I | Q8IZC7 | protein_coding | deleterious(0.04) | benign(0.394) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
ZNF101 | SNV | Missense_Mutation | rs746339800 | c.494N>A | p.Arg165Gln | p.R165Q | Q8IZC7 | protein_coding | deleterious(0.03) | benign(0.023) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ZNF101 | SNV | Missense_Mutation | novel | c.784N>C | p.Phe262Leu | p.F262L | Q8IZC7 | protein_coding | tolerated(0.09) | benign(0.097) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | novel | c.1277N>T | p.Arg426Met | p.R426M | Q8IZC7 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.54) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | rs774295128 | c.806G>A | p.Arg269Gln | p.R269Q | Q8IZC7 | protein_coding | tolerated(0.54) | benign(0.006) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | rs776249275 | c.1241N>T | p.Arg414Ile | p.R414I | Q8IZC7 | protein_coding | deleterious(0.04) | benign(0.394) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | novel | c.1191A>C | p.Lys397Asn | p.K397N | Q8IZC7 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | c.905N>T | p.Arg302Ile | p.R302I | Q8IZC7 | protein_coding | tolerated(0.1) | benign(0.061) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF101 | SNV | Missense_Mutation | rs774598408 | c.638N>A | p.Arg213Gln | p.R213Q | Q8IZC7 | protein_coding | tolerated(0.47) | benign(0) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |